Tuberculous and Non-Tuberculous Granulomatous Lymphadenitis in Patients Receiving ImatinibMesylate (Glivec) for Metastatic Gastrointestinal Stromal Tumor

Publisher： Karger

E-ISSN： 1662-6575|6|1|134-142

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.6, Iss.1, 2013-03, pp. : 134-142

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Prospective, Multicenter, Phase 2 Study of Imatinib Mesylate in Korean Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor

By  

Oncology, Vol. 76, Iss. 5, 2009-03 ,pp. : 326-332

Karger

Access to resources Recommend Favorite

Optimal Duration of Imatinib Mesylate Therapy in Metastatic Gastrointestinal Stromal Tumours

By  

Case Reports in Oncology, Vol. 4, Iss. 1, 2011-04 ,pp. : 204-210

Karger

Access to resources Recommend Favorite

Non-tuberculous mycobacterial infections

By Petrini Björn  

Scandinavian Journal of Infectious Diseases, Vol. 38, Iss. 4, 2006-04 ,pp. : 246-255

Informa Healthcare

Access to resources Recommend Favorite

Non-tuberculous mycobacteria in China

By Weimin Li   Guanglu Jiang   Zhihui Liu   Huakun Hao   Liquan Chai   Miao Tian   Xuxia Zhang   Tiangui Niu   Petrini Björn   Chuanyou Li  

Scandinavian Journal of Infectious Diseases, Vol. 39, Iss. 2, 2007-01 ,pp. : 138-141

Informa Healthcare

Access to resources Recommend Favorite

Imatinib Mesylate Treatment for Advanced Gastrointestinal Stromal Tumor: A Pilot Study Focusing on Patients Experiencing Sole Liver Metastasis after a Prior Radical Resection

By  

Oncology, Vol. 73, Iss. 5-6, 2008-05 ,pp. : 324-327

Karger

Access to resources Recommend Favorite